Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217330975> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W3217330975 abstract "Introduction. Renal cell carcinoma (RCC) represents about 2–3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC (mccRCC) with good or intermediate prognosis. However, about one-third of mccRCC patients do not respond to sunitinib, leading to disease progression. Methods. Here, we aim to find and characterize proteins associated with poor sunitinib response. Sixteen RCC tumors from patients responding (8) vs. non-responding (8) to sunitinib 3 months after treatment initiation were analyzed using data-independent acquisition mass spectrometry (DIA-MS) on Impact II LC-MS system (Bruker), together with their adjacent non-cancerous tissues in a pilot proteomics study. Validation was performed in an independent cohort of 75 mccRCC patients using DIA-MS on QExactive HF-X (Thermo Fisher Scientific), with data analysis in Spectronaut 13.9 (Biognosys). Transgelin protein role was functionally analyzed in RCC cell lines using CRISPR and RNAi silencing techniques. Results. Proteomics analysis quantified 1996 protein groups (FDR=0.01) and revealed 27 proteins deregulated between tumors non-responding vs. responding to sunitinib in the pilot study, representing a pattern of proteins potentially contributing to sunitinib resistance. Validation cohort confirmed up-regulation of transgelin in tumors non-responding to sunitinib and revealed its association with tumor grade. Gene set enrichment analysis showed an up-regulation of epithelial-to-mesenchymal transition with transgelin as one of the most significantly abundant proteins. Reduced transgelin protein level in CRISPR and RNAi altered RCC cells led to significantly slower proliferation of these cells and affected their survival. Conclusion. Altogether, our data indicate that transgelin is an essential protein supporting RCC cell proliferation, which could contribute to intrinsic sunitinib resistance, and is associated with aggressive phenotype of RCC tumors." @default.
- W3217330975 created "2021-12-06" @default.
- W3217330975 creator A5006324943 @default.
- W3217330975 creator A5010830790 @default.
- W3217330975 creator A5011327653 @default.
- W3217330975 creator A5017367590 @default.
- W3217330975 creator A5069592985 @default.
- W3217330975 creator A5072614457 @default.
- W3217330975 creator A5082994579 @default.
- W3217330975 creator A5085675986 @default.
- W3217330975 creator A5088540019 @default.
- W3217330975 date "2021-01-01" @default.
- W3217330975 modified "2023-09-27" @default.
- W3217330975 title "DIA-MS Identifies and Validates Transgelin as Protein Contributing to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment" @default.
- W3217330975 hasPublicationYear "2021" @default.
- W3217330975 type Work @default.
- W3217330975 sameAs 3217330975 @default.
- W3217330975 citedByCount "0" @default.
- W3217330975 crossrefType "journal-article" @default.
- W3217330975 hasAuthorship W3217330975A5006324943 @default.
- W3217330975 hasAuthorship W3217330975A5010830790 @default.
- W3217330975 hasAuthorship W3217330975A5011327653 @default.
- W3217330975 hasAuthorship W3217330975A5017367590 @default.
- W3217330975 hasAuthorship W3217330975A5069592985 @default.
- W3217330975 hasAuthorship W3217330975A5072614457 @default.
- W3217330975 hasAuthorship W3217330975A5082994579 @default.
- W3217330975 hasAuthorship W3217330975A5085675986 @default.
- W3217330975 hasAuthorship W3217330975A5088540019 @default.
- W3217330975 hasConcept C101544691 @default.
- W3217330975 hasConcept C104317684 @default.
- W3217330975 hasConcept C121608353 @default.
- W3217330975 hasConcept C126322002 @default.
- W3217330975 hasConcept C143998085 @default.
- W3217330975 hasConcept C170493617 @default.
- W3217330975 hasConcept C2777472916 @default.
- W3217330975 hasConcept C2778820342 @default.
- W3217330975 hasConcept C2779490328 @default.
- W3217330975 hasConcept C46111723 @default.
- W3217330975 hasConcept C502942594 @default.
- W3217330975 hasConcept C55493867 @default.
- W3217330975 hasConcept C71924100 @default.
- W3217330975 hasConcept C72563966 @default.
- W3217330975 hasConcept C86803240 @default.
- W3217330975 hasConceptScore W3217330975C101544691 @default.
- W3217330975 hasConceptScore W3217330975C104317684 @default.
- W3217330975 hasConceptScore W3217330975C121608353 @default.
- W3217330975 hasConceptScore W3217330975C126322002 @default.
- W3217330975 hasConceptScore W3217330975C143998085 @default.
- W3217330975 hasConceptScore W3217330975C170493617 @default.
- W3217330975 hasConceptScore W3217330975C2777472916 @default.
- W3217330975 hasConceptScore W3217330975C2778820342 @default.
- W3217330975 hasConceptScore W3217330975C2779490328 @default.
- W3217330975 hasConceptScore W3217330975C46111723 @default.
- W3217330975 hasConceptScore W3217330975C502942594 @default.
- W3217330975 hasConceptScore W3217330975C55493867 @default.
- W3217330975 hasConceptScore W3217330975C71924100 @default.
- W3217330975 hasConceptScore W3217330975C72563966 @default.
- W3217330975 hasConceptScore W3217330975C86803240 @default.
- W3217330975 hasLocation W32173309751 @default.
- W3217330975 hasOpenAccess W3217330975 @default.
- W3217330975 hasPrimaryLocation W32173309751 @default.
- W3217330975 isParatext "false" @default.
- W3217330975 isRetracted "false" @default.
- W3217330975 magId "3217330975" @default.
- W3217330975 workType "article" @default.